- Update of Drug-induced Kidney Injury
-
Lee H
- KMID: 2534683
- J Pharmacoepidemiol Risk Manage.
- 2022 Sep;14(2):125-132.
- doi: 10.56142/jperm.22.0018
Drug-induced kidney injury is one of the common causes of community- or hospital-acquired kidney injury as well as the adverse effects of drugs. Drugs’ innate kidney toxicity, patients having multiple... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent Change of the Etiology of Drug Induced Anaphylaxis in a Korean Tertiary Care Hospital
-
Park JW
- KMID: 2534681
- J Pharmacoepidemiol Risk Manage.
- 2022 Sep;14(2):109-113.
- doi: 10.56142/jperm.22.0010
Drug induced anaphylaxis is one of critical threat for patients’ safety in general hospital, and how to mitigate the evitable onset of anaphylaxis is crucial factor in the patient safety... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Atypical Fixed Drug Eruption Induced by Erdosteine
-
Choi JW, Kim HJ, Yoon J, Seo JH, Lee JY, Kang HR
- KMID: 2534688
- J Pharmacoepidemiol Risk Manage.
- 2022 Sep;14(2):165-168.
- doi: 10.56142/jperm.22.0013
Erdosteine is a mucolytic agent used in acute and chronic respiratory disease and it is known to be well tolerated. Adverse drug reactions related with erdosteine are mostly mild gastrointestinal... -
- CITED
-
- Close
- SHARE
-
- Close
- Introducing Patient Safety Activities in Canada: Focused on Medication Incidents and Preventions
-
Kim SJ, Yang J, Jung SY, Lim JY, Yoon H, Park H, Lee M
- KMID: 2534682
- J Pharmacoepidemiol Risk Manage.
- 2022 Sep;14(2):114-124.
- doi: 10.56142/jperm.22.0011
Patient safety (PS) in healthcare organizations is an important problem worldwide. A patient safety reporting and learning system has been proposed as a means to keep patients safe. Canada operates... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case Report of Guaifenesin-Induced Anaphylaxis
-
Yoon J, Kim HJ, Seo JH, Kang HR
- KMID: 2534689
- J Pharmacoepidemiol Risk Manage.
- 2022 Sep;14(2):169-172.
- doi: 10.56142/jperm.22.0016
Guaifenesin (glyceryl guaiacolate) is widely used as an expectorant by reducing the viscosity and increasing the volume of bronchial secretions. It is usually used as a combination complex with acetaminophen,... -
- CITED
-
- Close
- SHARE
-
- Close
- Systematic Review for Remdesivir Use in Pediatric Patients under 3.5 kg with COVID-19
-
Cho WB, Lee NY, Ah YM
- KMID: 2534680
- J Pharmacoepidemiol Risk Manage.
- 2022 Sep;14(2):101-108.
- doi: 10.56142/jperm.22.0007
Objective: We aimed to identify the safety and efficacy of remdesivir in pediatric COVID-19 patients less than 3.5 kg by systematic review. Methods: We conducted a literature search using MEDLINE,... -
- CITED
-
- Close
- SHARE
-
- Close
- Lactic Acidosis Adverse Drug Reaction Reporting Aspect Evaluation of Hepatitis B Treatment Using Korea Adverse Event Reporting System
-
Lee S, Kwon M, Lee S, Kim J
- KMID: 2534685
- J Pharmacoepidemiol Risk Manage.
- 2022 Sep;14(2):144-148.
- doi: 10.56142/jperm.22.0012
Chronic hepatitis B is caused by the hepatitis B virus and is known as a major cause of chronic liver disease with a high worldwide prevelance. And it has a... -
- CITED
-
- Close
- SHARE
-
- Close
- Incidence and Associated Factors of Linezolid Associated Lactic Acidosis
-
Park SY, Baek JU, Kim KA, Choi GW, Baek JH, Jo YH, Cho YS, Ryu HG, Lee5 JY, Kim AJ
- KMID: 2534687
- J Pharmacoepidemiol Risk Manage.
- 2022 Sep;14(2):158-164.
- doi: 10.56142/jperm.22.0015
Objective: Incidence of linezolid-associated lactic acidosis (LALA) has been described as 5-7% in previous studies.However, limited studies have evaluated the association between linezolid and lactic acidosis, and there is a... -
- CITED
-
- Close
- SHARE
-
- Close
- Case Analysis in Drug Approval by FDA/EMA Using Real-World Data/Real-World Evidence
-
Song J, Kim J, Park S, Kim JH, Noh Y, Sung HG, Shin JY
- KMID: 2534684
- J Pharmacoepidemiol Risk Manage.
- 2022 Sep;14(2):133-143.
- doi: 10.56142/jperm.22.0009
In recent years, regulators have been willing to use real-world data (RWD) and real-world evidence (RWE) to support their regulatory decisions in various areas, such as initial marketing authorizations, expanding... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-world Data-based Adverse Drug Reactions Analysis of Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma
-
Ko M, Choi J, Kim S, Kim SH, Cho EJ, Cho YS, Koh YI, Oh JM
- KMID: 2534686
- J Pharmacoepidemiol Risk Manage.
- 2022 Sep;14(2):149-157.
- doi: 10.56142/jperm.22.0014
Objective: Pomalidomide is a latest-approved immunomodulatory drug used with dexamethasone for patients with relapsed or refractory multiple myeloma (RRMM). However, the real-world safety evidence remains unclear. Thus, we evaluated the... -
- CITED
-
- Close
- SHARE
-
- Close
